Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 0.60 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3211247 | 1.00 | PPARG (0.60) | PPARGAPPMAPTSCN9AHDAC8 | |
| SCHEMBL3217303 | 0.88 | PPARG (0.66) | PPARGHDAC8 | |
| SCHEMBL3217283 | 0.88 | PPARG (0.66) | PPARGHDAC8 | |
| SCHEMBL3216162 | 0.87 | PPARG (0.63) | PPARGSCN9AHDAC8 | |
| SCHEMBL3216149 | 0.87 | PPARG (0.63) | PPARGSCN9AHDAC8 | |
| SCHEMBL3218961 | 0.83 | PPARG (0.66) | PPARGHDAC8 | |
| SCHEMBL3218950 | 0.83 | PPARG (0.66) | PPARGHDAC8 | |
| SCHEMBL3202441 | 0.82 | PPARG (0.56) | PPARGSCN9A | |
| SCHEMBL3209900 | 0.82 | MAPT (0.55) | APPMAPTSCN9AHDAC8KDM4E | |
| SCHEMBL3209916 | 0.82 | MAPT (0.55) | APPMAPTSCN9AHDAC8KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041892-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2010-02-18 | — | — | US | disclosed |
| US-20090270631-A1 | Therapeutic agent for diabetes | ABE HIDENORI | 2009-10-29 | — | — | US | disclosed |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270631-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | PPARG 31/4885APP 3197/4885MAPT 4588/4885 |
| US-20080009530-A1 | Therapeutic Agent for Diabetes | FABP4, SLC5A1, SLC5A2 | PPARG 30/4885APP 3588/4885MAPT 4612/4885 |
| US-20100041892-A1 | Therapeutic agent for diabetes | FABP4, SLC5A1, SLC5A2 | PPARG 31/4885APP 3197/4885MAPT 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.